REFERENCES
1. Barberi C, van den Hondel KE. The use of cardiac troponin T (cTnT) in the postmortem diagnosis of acute myocardial infarction and sudden cardiac death: a systematic review. Forensic Sci Int 2018;292:27-38.
2. Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American heart association. Circulation 2021;143:e254-743.
3. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on management of acute myocardial infarction). Circulation 1996;94:2341-50.
4. Phillips SJ, Kongtahworn C, Zeff RH, et al. Emergency coronary artery revascularization: a possible therapy for acute myocardial infarction. Circulation 1979;60:241-6.
5. Elbadawi A, Elgendy IY, Mahmoud K, et al. Temporal trends and outcomes of mechanical complications in patients with acute myocardial infarction. JACC Cardiovasc Interv 2019;12:1825-36.
6. Ouaddi NE, de Diego O, Labata C, et al. Mechanical complications in STEMI: prevalence and mortality trends in the primary PCI era. The Ruti-STEMI registry. Rev Esp Cardiol 2023;76:427-33.
7. Weiss ES, Chang DD, Joyce DL, Nwakanma LU, Yuh DD. Optimal timing of coronary artery bypass after acute myocardial infarction: a review of California discharge data. J Thorac Cardiovasc Surg 2008;135:503-11.e3.
8. Abd-Alaal MM, Alsabban MA, Abbas OA, Alshaer AA, Al-Saddique A, Fouda M. Timing of revascularization after acute myocardial infarction. Asian Cardiovasc Thorac Ann 2010;18:118-21.
9. Ngaage DL, Sogliani F, Tang A. Early and late prognostic implications of coronary artery bypass timing after myocardial infarction. Eur J Cardiothorac Surg 2013;43:549-54.
10. Grieshaber P, Roth P, Oster L, et al. Is delayed surgical revascularization in acute myocardial infarction useful or dangerous? New insights into an old problem. Interact Cardiovasc Thorac Surg 2017;25:772-9.
11. Yau TH, Chong MH, Brigden ZM, Ngemoh D, Harky A, Bin Saeid J. The timing of surgical revascularization in acute myocardial infarction: when should we intervene? J Cardiovasc Surg 2022;63:179-86.
12. Smilowitz NR, Feit F. The history of primary angioplasty and stenting for acute myocardial infarction. Curr Cardiol Rep 2016;18:5.
13. Julian DG. Treatment of cardiac arrest in acute myocardial ischaemia and infarction. Lancet 1961;2:840-4.
14. De Caterina R, Giannessi D, Bernini W, et al. Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction. Am J Cardiol 1985;55:589-90.
15. De Caterina R, Giannessi D, Bernini W, et al. Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function. Eur Heart J 1985;6:409-17.
16. Montinari MR, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots - a concise summary. Vascul Pharmacol 2019;113:1-8.
17. Fletcher AP, Alkjaersig N, Smyrniotis FE, Sherry S. The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physician 1958;71:287-96.
18. Yusuf S. Interventions that potentially limit myocardial infarct size: overview of clinical trials. Am J Cardiol 1987;60:11A-7A.
19. Keon WJ, Abbas SZ, Shankar KR, Cohen G, Akyrekli Y, Nino AF. Emergency aorto-coronary venous bypass graft in cardiogenic shock. Can Med Assoc J 1971;105:1293-6.
20. DeWood MA, Spores J, Berg R Jr, et al. Acute myocardial infarction: a decade of experience with surgical reperfusion in 701 patients. Circulation 1983;68:Ii8-16.
21. Keon WJ, Bedard P, Shankar KR, Akyurekli Y, Nino A, Berkman F. Experience with emergency aortocoronary bypass grafts in the presence of acute myocardial infarction. Circulation 1973;48:III151-5.
22. Koshal A, Beanlands DS, Davies RA, Nair RC, Keon WJ. Urgent surgical reperfusion in acute evolving myocardial infarction. A randomized controlled study. Circulation 1988;78:I171-8.
23. Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61-8.
24. Hartzler GO, Rutherford BD, McConahay DR. Percutaneous transluminal coronary angioplasty: application for acute myocardial infarction. Am J Cardiol 1984;53:117C-21C.
25. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20.
26. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2022;145:e4-17.
27. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The primary angioplasty in myocardial infarction study group. N Engl J Med 1993;328:673-9.
28. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336:1621-8.
29. Berger PB, Ellis SG, Holmes DR Jr, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in acute coronary syndromes (GUSTO-IIb) trial. Circulation 1999;100:14-20.
30. Byrne RA, Rossello X, Coughlan JJ, et al. ESC Scientific Document Group. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44:3720-826.
31. Bernard C, Morgant MC, Jazayeri A, et al. Optimal timing of coronary artery bypass grafting in haemodynamically stable patients after myocardial infarction. Biomedicines 2023;11:979.
32. Biancari F, Onorati F, Rubino AS, et al. Outcome of emergency coronary artery bypass grafting. J Cardiothorac Vasc Anesth 2015;29:275-82.
33. Chen HL, Liu K. Timing of coronary artery bypass graft surgery for acute myocardial infarction patients: a meta-analysis. Int J Cardiol 2014;177:53-6.
34. Lang Q, Qin C, Meng W. Appropriate timing of coronary artery bypass graft surgery for acute myocardial infarction patients: a meta-analysis. Front Cardiovasc Med 2022;9:794925.
35. Maganti M, Brister SJ, Yau TM, Collins S, Badiwala M, Rao V. Changing trends in emergency coronary bypass surgery. J Thorac Cardiovasc Surg 2011;142:816-22.
36. Klempfner R, Barac YD, Younis A, et al. Early referral to coronary artery bypass grafting following acute coronary syndrome, trends and outcomes from the acute coronary syndrome israeli survey (ACSIS) 2000-2010. Heart Lung Circ 2018;27:175-82.
37. Lemaire A, Vagaonescu T, Ikegami H, Volk L, Verghis N, Lee LY. Delay in coronary artery bypass grafting for STEMI patients improves hospital morbidity and mortality. J Cardiothorac Surg 2020;15:86.
38. Liakopoulos OJ, Slottosch I, Wendt D, et al. Surgical revascularization for acute coronary syndromes: a report from the North Rhine-Westphalia surgical myocardial infarction registry. Eur J Cardiothorac Surg 2020;58:1137-44.
39. Thielmann M, Neuhäuser M, Marr A, et al. Predictors and outcomes of coronary artery bypass grafting in ST elevation myocardial infarction. Ann Thorac Surg 2007;84:17-24.
40. Bianco V, Kilic A, Gleason TG, et al. Timing of coronary artery bypass grafting after acute myocardial infarction may not influence mortality and readmissions. J Thorac Cardiovasc Surg 2021;161:2056-64.e4.
41. Sintek CF, Pfeffer TA, Khonsari S. Surgical revascularization after acute myocardial infarction. J Thorac Cardiovasc Surg 1994;107:1317-22.
42. Fransen E, Maessen J, Dentener M, Senden N, Geskes G, Buurman W. Systemic inflammation present in patients undergoing CABG without extracorporeal circulation. Chest 1998;113:1290-5.
43. Anzai T, Yoshikawa T, Shiraki H, et al. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 1997;96:778-84.
44. Pietilä K, Harmoinen A, Pöyhönen L, Ruosteenoja R. C-reactive protein in subendocardial and transmural myocardial infarcts. Clin Chem 1986;32:1596-7.
45. Parikh SV, de Lemos JA, Jessen ME, et al. CRUSADE and ACTION Registry-GWTG Participants. Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National cardiovascular data registry ACTION registry-GWTG (acute coronary treatment and intervention outcomes network registry-get with the guidelines). JACC Cardiovasc Interv 2010;3:419-27.
46. Kite TA, Kurmani SA, Bountziouka V, et al. Timing of invasive strategy in non-ST-elevation acute coronary syndrome: a meta-analysis of randomized controlled trials. Eur Heart J 2022;43:3148-61.
47. Park DW, Clare RM, Schulte PJ, et al. Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. JAMA 2014;312:2019-27.
48. Steg PG, James SK, Atar D, et al. Task Force on the management of ST-segment elevation acute myocardial infarction of the European society of cardiology (ESC). ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-619.
49. Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol 2016;67:1235-50.
50. De Innocentiis C, Zimarino M, De Caterina R. Is complete revascularisation mandated for all patients with multivessel coronary artery disease? Interv Cardiol 2018;13:45-50.
51. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization. EuroIntervention 2015;10:1024-94.
52. Vlaar PJ, Mahmoud KD, Holmes DR Jr, et al. Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis. J Am Coll Cardiol 2011;58:692-703.
53. Ebrahimi R, Dyke C, Mehran R, et al. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2009;53:1965-72.
54. Fox KA, Mehta SR, Peters R, et al. Clopidogrel in unstable angina to prevent recurrent ischemic events trial. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) Trial. Circulation 2004;110:1202-8.
55. Smith PK, Goodnough LT, Levy JH, et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol 2012;60:388-96.
56. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Kardiol Pol 2017;75:1217-99.
57. Mehta SR, Bainey KR, Cantor WJ, et al. members of the Secondary Panel. 2018 Canadian cardiovascular society/Canadian association of interventional cardiology focused update of the guidelines for the use of antiplatelet therapy. Can J Cardiol 2018;34:214-33.
58. Gherli R, Mariscalco G, Dalén M, et al. Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting. JAMA Cardiol 2016;1:921-8.
59. Schultz-Lebahn A, Nissen PH, Pedersen TF, Tang M, Hvas AM. Platelet function assessed by ROTEM(®)platelet in patients receiving antiplatelet therapy during cardiac and vascular surgery. Scand J Clin Lab Invest 2022;82:18-27.
60. Sibbing D, Aradi D, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding p2Y(12) receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv 2019;12:1521-37.
61. Bhatt DL, Pollack CV, Weitz JI, et al. Antibody-based ticagrelor reversal agent in healthy volunteers. N Engl J Med 2019;380:1825-33.
62. Bhatt DL, Pollack CV, Mazer CD, et al. Bentracimab for ticagrelor reversal in patients undergoing urgent surgery. NEJM Evidence 2022;1:3.
63. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012;141:e326S-50S.
64. Alquwaizani M, Buckley L, Adams C, Fanikos J. Anticoagulants: a review of the pharmacology, dosing, and complications. Curr Emerg Hosp Med Rep 2013;1:83-97.
